Suggested remit: To appraise the clinical and cost effectiveness of tisotumab vedotin within its marketing authorisation for treating recurrent or metastatic cervical cancer after chemotherapy.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 3753
Provisional Schedule
- Expected publication:
- 12 June 2026
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email TACommA@nice.org.uk
Stakeholders
- Companies sponsors
- GenMAB a/s
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists (RCR)
- Associated public health groups
- Public Health Wales
- UK Health Security Agency (Formerly Public Health England)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary (BNF)
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 February 2026 | Committee meeting: 1 |
| 10 February 2026 | Declaration of interests |
| 08 July 2025 | Invitation to participate |
| 07 May 2025 - 05 June 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3753 |
| 07 May 2025 | In progress. Scoping commencing |
| 23 July 2024 | Note - Note added to the project documents |
| 07 December 2023 | Note - Note added to the project documents |
| 02 June 2020 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual